Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2019

View Archived Issues

Killer T cells protected by membrane lipid order and charge

Enterovirus contributes to islet autoimmunity

CARsgen Therapeutics receives IND clearance for AB-011 in China

Scohia Pharma initiates phase I study of SCO-267

IND for HLX-10 plus HLX-07 antibody combination therapy approved in China

FDA clears IND application for first-in-human study of CPT-31

Intrathecal AVXS-301 shows promise in preclinical models of ALS

Implicit Bioscience presents phase I data for IC-14 in motor neuron disease

Anti-BCMA CAR-T candidate C-CAR088 shows early clinical efficacy

Pfizer gives details on the discovery of novel noncovalent modulator of hemoglobin

First-in-human study of LOXO-305 confirms it as a potent anti-BTK agent for B-cell malignancies

The anti-CD33/CD3 BiTE AMG-673 shows promise as treatment for relapsed/refractory AML

GenSight reports on REALITY registry study in support of Lumevoq

Three phase III trials of tralokinumab in atopic dermatitis meet endpoints

Xeris reports in-clinic stage data from phase II trial of RTU glucagon

Constellation Pharmaceuticals patents EZH2 inhibitors

Primmune Therapeutics discloses new TLR7 agonists

VenatoRx Pharmaceuticals patent details bacterial PBP3 inhibitors

Alligator initiates first-in-human study of 4-1BB antibody ATOR-1017

University of Texas System identifies KRAS-targeting compounds

hSTING agonists described in Incyte patent

Iterum reports topline data from phase III trial of sulopenem in cIAI

EicOsis initiates phase I trial of sEH inhibitor EC-5026 for pain

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...